查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1383655

二尖瓣疾病市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按治療類型、適應症、最終用戶、地區、競爭細分

Mitral Valve Disease Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028 Segmented By Treatment Type, By Indication, By End-User, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年全球二尖瓣疾病市場價值為 27.5 億美元，預計在預測期內將出現令人印象深刻的成長，到 2028 年複合CAGR為8.90%。全球二尖瓣疾病市場在更廣泛的心血管保健領域中呈現動態格局。二尖瓣疾病是指影響二尖瓣的一組疾病，二尖瓣調節心臟左心房和左心室之間的血流。這些情況會導致疲勞、呼吸急促和心律不整等症狀，最終影響患者的生活品質。該市場圍繞著二尖瓣疾病的診斷、治療和管理。

主要市場促進因素

技術進步

市場概況
預測期 2024-2028
2022 年市場規模 27.5億美元
2028 年市場規模 45.5億美元
2023-2028 年CAGR 8.90%
成長最快的細分市場 醫院
最大的市場 北美洲

技術進步在塑造全球二尖瓣疾病市場格局方面發揮了關鍵作用。近年來，心臟病學領域在診斷和治療方式方面取得了顯著進展。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和次要最終用戶
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球二尖瓣疾病市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依治療類型（修復、置換、心臟再同步治療、治療）
    • 依適應症（狹窄、脫垂、逆流）
    • 按最終使用者（醫院、門診手術中心、其他）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：北美二尖瓣疾病市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療類型
    • 按指示
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲二尖瓣疾病市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療類型
    • 按指示
    • 按最終用戶
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區二尖瓣疾病市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療類型
    • 按指示
    • 按最終用戶
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲二尖瓣疾病市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療類型
    • 按指示
    • 按最終用戶
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲二尖瓣疾病市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療類型
    • 按指示
    • 按最終用戶
  • MEA：國家分析
    • 南非 二尖瓣疾病
    • 沙烏地阿拉伯 二尖瓣疾病
    • 阿拉伯聯合大公國 二尖瓣疾病

第 11 章：市場動態

  • 促進因素與挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：全球二尖瓣疾病市場：SWOT 分析

第14章：競爭格局

  • Corcym英國有限公司
  • 雅培實驗室公司
  • Zydus 生命科學有限公司
  • 美敦力公司
  • 愛德華茲生命科學公司
  • 富裕醫療公司
  • 衝擊波醫療公司
  • 華凱醫療
  • 輝瑞公司
  • 梯瓦製藥工業股份有限公司

第 15 章：策略建議

第 16 章：關於我們與免責聲明

簡介目錄
Product Code: 17684

Global Mitral Valve Disease Market has valued at USD 2.75 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.90% through 2028. The Global Mitral Valve Disease Market encompasses a dynamic landscape within the broader realm of cardiovascular healthcare. Mitral valve disease refers to a group of conditions affecting the mitral valve, which regulates blood flow between the left atrium and the left ventricle of the heart. These conditions can lead to symptoms such as fatigue, shortness of breath, and irregular heartbeats, ultimately impacting patients' quality of life. This market revolves around the diagnosis, treatment, and management of mitral valve diseases.

Key Market Drivers

Technological Advancements

Market Overview
Forecast Period2024-2028
Market Size 2022USD 2.75 Billion
Market Size 2028USD 4.55 Billion
CAGR 2023-20288.90%
Fastest Growing SegmentHospitals
Largest MarketNorth America

Technological advancements have played a pivotal role in shaping the landscape of the Global Mitral Valve Disease Market. In recent years, the field of cardiology has witnessed remarkable progress in diagnostic and treatment modalities.

Advanced imaging techniques such as 3D echocardiography and cardiac magnetic resonance imaging (CMR) have revolutionized the accuracy of diagnosing mitral valve diseases. These technologies provide intricate insights into the structure and function of the mitral valve, enabling healthcare professionals to make more informed decisions. Moreover, minimally invasive surgical procedures have gained prominence, offering patients less postoperative pain, shorter hospital stays, and quicker recovery times. Procedures like transcatheter mitral valve repair (TMVR) have emerged as less invasive alternatives to open-heart surgeries, expanding treatment options and improving patient outcomes.

Increasing Prevalence of Cardiovascular Diseases

Cardiovascular diseases, including mitral valve diseases, have witnessed a surge in prevalence globally. Several factors contribute to this concerning trend, including changing lifestyles, an aging population, and an increase in risk factors like obesity and hypertension.

The aging population is particularly significant, as age is a known risk factor for mitral valve diseases. As individuals grow older, the likelihood of developing structural heart problems, including mitral valve issues, increases. This demographic shift has led to a growing pool of patients in need of medical attention and interventions. Furthermore, the changing dietary habits and sedentary lifestyles in many parts of the world have contributed to the rise in cardiovascular diseases, creating a substantial demand for mitral valve disease treatments.

Rising Awareness

In recent years, there has been a notable increase in awareness about mitral valve diseases among both healthcare professionals and the general public. This heightened awareness has led to earlier diagnoses and a proactive approach to managing these conditions.

Educational campaigns, medical conferences, and advocacy groups have all played a part in disseminating knowledge about the importance of timely diagnosis and treatment. Patients are now more likely to seek medical attention when they experience symptoms like shortness of breath, chest pain, or irregular heartbeats, which are indicative of mitral valve issues. Additionally, healthcare providers are better equipped to recognize and diagnose mitral valve diseases, thanks to improved training and access to advanced diagnostic tools. This increased awareness and early intervention have positively impacted patient outcomes.

Favorable Reimbursement Policies

The availability of favorable reimbursement policies for mitral valve disease treatments has incentivized both healthcare providers and patients to pursue necessary interventions. Insurance coverage and government programs that support these treatments have made them more accessible and affordable to a broader spectrum of the population.

These policies reduce the financial burden on patients and encourage them to seek appropriate care without hesitation. They also provide a level of financial security for healthcare institutions, making it economically viable for them to offer specialized mitral valve disease treatments and procedures. The Global Mitral Valve Disease Market is being driven by technological advancements, the increasing prevalence of cardiovascular diseases, rising awareness, and favorable reimbursement policies. These factors collectively contribute to the growth of this market and the improved care of patients suffering from mitral valve diseases.

Key Market Challenges

High Treatment Costs

One of the primary challenges facing the growth of the Global Mitral Valve Disease Market is the high cost associated with diagnosis and treatment. Mitral valve diseases often require complex surgical interventions or implantation of prosthetic valves, which can be prohibitively expensive for many patients and healthcare systems.

Mitral valve surgeries, whether traditional open-heart procedures or minimally invasive techniques like transcatheter mitral valve repair (TMVR), involve substantial costs. These expenses encompass surgeon fees, operating room charges, and the cost of prosthetic valves.

Recovery and post-operative care for mitral valve disease patients can be extensive, driving up healthcare costs. Frequent follow-up appointments, medications, and cardiac rehabilitation programs all contribute to the financial burden. In some regions, insurance coverage for mitral valve disease treatments may be limited or inadequate. This lack of comprehensive coverage can deter patients from seeking timely medical attention and hinder the market's growth.

Limited Access to Advanced Healthcare Services

Access to advanced healthcare services, especially in rural or underserved areas, remains a significant challenge in mitigating mitral valve diseases. Disparities in healthcare infrastructure and resources can limit the timely diagnosis and treatment of patients.

Rural or remote regions often lack the specialized medical facilities and expert healthcare providers required for diagnosing and treating mitral valve diseases. Patients in these areas may face extended travel times to reach appropriate healthcare centers.

High out-of-pocket expenses, coupled with limited insurance coverage, can create financial barriers that hinder access to quality care. This is particularly problematic for individuals with limited financial resources. Shortages of skilled cardiac surgeons and cardiologists in some areas can result in longer wait times for treatments and surgeries. Delayed interventions can lead to worsened patient outcomes.

Regulatory and Compliance Challenges

The Global Mitral Valve Disease Market is subject to stringent regulatory requirements and compliance standards imposed by health authorities. Navigating these regulations, obtaining necessary approvals, and ensuring compliance can pose significant challenges for manufacturers and healthcare institutions.

Bringing new mitral valve disease treatment options to the market often requires conducting extensive clinical trials to demonstrate safety and efficacy. Meeting these rigorous trial standards can be time-consuming and expensive.

Gaining regulatory approvals from agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) can be a lengthy and complex process. Delays in approvals can slow down the introduction of innovative treatments. Manufacturers and healthcare providers must adhere to strict quality control and compliance standards. Ensuring that products and procedures meet these standards can be resource-intensive and demanding.

Key Market Trends

Minimally Invasive Procedures on the Rise:

One prominent trend in the Global Mitral Valve Disease Market is the increasing adoption of minimally invasive procedures for the diagnosis and treatment of mitral valve diseases. Traditionally, open-heart surgery was the standard approach for mitral valve repair or replacement. However, advances in medical technology have led to the development of less invasive alternatives, such as transcatheter mitral valve repair (TMVR) and transcatheter mitral valve replacement (TMVR).

Minimally invasive procedures offer several advantages, including smaller incisions, reduced pain, shorter hospital stays, and quicker recovery times. Patients are increasingly opting for these less invasive options, contributing to their popularity.

The availability of minimally invasive techniques has expanded the range of patients who can undergo mitral valve interventions. High-risk or elderly patients who may not be suitable candidates for open-heart surgery can now benefit from these innovative procedures. Healthcare professionals are gaining expertise in performing minimally invasive mitral valve procedures, further boosting their adoption. This trend is likely to continue as more specialists become proficient in these techniques.

Advancements in Implantable Devices:

Another significant trend in the Global Mitral Valve Disease Market is the continuous advancement of implantable devices used for mitral valve repair and replacement. Prosthetic valves and devices are undergoing constant innovation to improve their performance and durability.

Recent developments have led to prosthetic valves with longer lifespans. This is crucial, as it reduces the need for repeat surgeries and improves the overall quality of life for patients.

Manufacturers are increasingly offering customizable prosthetic valves to better match individual patient anatomy. This customization enhances the effectiveness of valve replacement and minimizes complications. Implantable devices are now being made with biocompatible materials that reduce the risk of adverse reactions or complications. These materials improve the long-term performance of the devices.

Telemedicine and Remote Monitoring:

In recent years, the adoption of telemedicine and remote monitoring solutions in the field of cardiology, including mitral valve disease management, has gained momentum. This trend has been further accelerated by the COVID-19 pandemic, which highlighted the importance of remote healthcare delivery.

Telemedicine allows patients to consult with healthcare professionals from the comfort of their homes, overcoming geographical barriers and ensuring that even those in remote areas can access specialized care.

Remote monitoring solutions enable continuous tracking of patients' cardiac health. This real-time data allows for early detection of complications and adjustments to treatment plans, enhancing patient outcomes. Telemedicine can result in cost savings for both patients and healthcare systems. Fewer in-person visits and hospitalizations lead to reduced healthcare expenditures, making care more affordable and sustainable.

Segmental Insights

Treatment Type Insights

Based on the category of Treatment Type, the mitral valve repair segment emerged as the dominant player in the global market for Mitral Valve Disease in 2022. Mitral valve repair is favored for its ability to preserve the patient's native valve tissue, known as the "valvuloplasty" approach. Unlike mitral valve replacement, where the damaged valve is entirely replaced with a prosthetic one, repair techniques aim to restore and reconstruct the patient's natural valve. Repair maintains the functionality of the patient's own valve, allowing it to continue regulating blood flow effectively. This is crucial for long-term cardiac health. Since the native tissue is retained, there is a reduced risk of complications associated with prosthetic valves, such as blood clots, infections, and valve-related degeneration. Patients who undergo successful mitral valve repair typically experience better postoperative outcomes, including fewer symptoms, improved exercise capacity, and a higher quality of life.

The advent of minimally invasive surgical techniques, such as robotic-assisted surgery and transcatheter mitral valve repair (TMVR), has significantly boosted the popularity of mitral valve repair. These less invasive approaches offer numerous benefits: Minimally invasive procedures involve smaller incisions, resulting in less surgical trauma, reduced pain, and shorter hospital stays. Patients recover more quickly compared to traditional open-heart surgery.

The minimally invasive approach expands the pool of eligible patients who can undergo mitral valve repair. High-risk and elderly patients, who may not be candidates for extensive open-heart surgery, can benefit from these innovative techniques. Shorter hospital stays and quicker recovery times translate into cost savings for both patients and healthcare systems, making mitral valve repair an economically viable option. Cardiac surgeons receive specialized training and hands-on experience in mitral valve repair, allowing them to perform these intricate procedures with confidence and precision. Ongoing medical education and continuous professional development ensure that cardiac surgeons stay at the forefront of mitral valve repair techniques and technologies. Surgeons' expertise directly correlates with patient outcomes. High success rates and favorable experiences reported by patients contribute to the growing preference for mitral valve repair. These factors are expected to drive the growth of this segment.

Indication Insight

Based on the category of Indication, the mitral valve regurgitation segment emerged as the dominant player in the global market for Mitral Valve Disease in 2022. Mitral valve regurgitation is the most common indication within the realm of mitral valve disease. This condition occurs when the mitral valve does not close tightly, leading to the backward flow of blood into the left atrium during each heartbeat. As individuals age, the risk of developing mitral valve regurgitation increases. Age-related changes in the structure and function of the mitral valve can lead to regurgitation.

MVR often occurs as a secondary condition in individuals with other heart conditions, such as coronary artery disease, heart attacks, and cardiomyopathy. Certain lifestyle factors, including smoking, obesity, and a sedentary lifestyle, can contribute to the development of MVR. These risk factors are prevalent in many parts of the world. Mitral valve regurgitation exists along a spectrum, with varying degrees of severity. This diversity in disease presentation contributes to the prominence of the MVR category in the market: MVR can range from mild, where the regurgitation is minimal and may not require immediate intervention, to severe, where the regurgitation significantly impairs cardiac function and warrants prompt treatment. The ability to intervene at different stages of MVR provides a broad scope for healthcare providers to offer timely and appropriate treatments, including surgical repair or replacement.

Recent advances in medical technology and diagnostic tools have improved the accuracy of diagnosing MVR and expanded the treatment options available for patients: Echocardiography, including 3D and transesophageal echocardiography, allows for precise assessment of the mitral valve, enabling early detection and characterization of regurgitation. The field of cardiac surgery has witnessed the development of innovative procedures for treating MVR, such as minimally invasive approaches like robotic-assisted surgery and transcatheter mitral valve repair (TMVR). Tailoring treatment strategies to the severity of MVR and the patient's overall health allows for personalized care plans that optimize outcomes.

End-User Insights

The hospital segment is projected to experience rapid growth during the forecast period. Hospitals, especially those with specialized cardiac care units and departments, are equipped with the expertise and infrastructure required for the comprehensive management of mitral valve disease. This includes the presence of cardiac surgeons, interventional cardiologists, and other healthcare professionals with the necessary skills to address mitral valve-related issues. Hospitals typically have access to state-of-the-art diagnostic equipment and facilities. This includes echocardiography labs, cardiac catheterization labs, and advanced imaging technologies like cardiac magnetic resonance imaging (CMR). These resources allow for accurate and timely diagnosis of mitral valve diseases, which is crucial for treatment planning.

Mitral valve diseases can vary in severity, and treatment options range from medication and lifestyle modifications to surgical interventions. Hospitals are well-equipped to offer a wide range of treatment modalities, including Hospitals can provide medications to manage symptoms and slow the progression of mitral valve disease. Hospitals can perform minimally invasive procedures such as transcatheter mitral valve repair (TMVR) or surgical mitral valve repair, which require specialized equipment and skilled healthcare teams. For severe cases, open-heart surgery for mitral valve replacement or repair is often necessary. Hospitals have the surgical facilities and expertise to perform these complex procedures.

Following surgical interventions or other treatments, patients require postoperative care and cardiac rehabilitation. Hospitals are well-equipped to provide this crucial phase of patient recovery, ensuring that individuals regain their strength and cardiovascular health. Hospitals promote collaboration among various medical specialties, including cardiology, cardiothoracic surgery, anesthesia, and nursing, to deliver comprehensive care to mitral valve disease patients. This multidisciplinary approach is essential for optimizing patient outcomes. These factors collectively contribute to the growth of this segment.

Regional Insights

North America emerged as the dominant player in the global Mitral Valve Disease market in 2022, holding the largest market share in terms of both value and volume. North America boasts a well-developed healthcare infrastructure with access to cutting-edge technologies, specialized cardiac care centers, and a skilled healthcare workforce. The region has a high prevalence of cardiovascular diseases, including mitral valve diseases, primarily due to factors like an aging population, lifestyle-related risk factors, and advanced diagnostic capabilities. North America leads in technological advancements, including minimally invasive procedures, which are preferred for mitral valve disease treatment. The region invests significantly in research and development, contributing to the development of innovative treatment modalities and medical devices.

The Asia-Pacific market is poised to be the fastest-growing market, offering lucrative growth opportunities for Mitral Valve Disease players during the forecast period. Factors such as Asia-Pacific continue to grow, there is an increased capacity for healthcare spending, leading to improved access to advanced cardiac care and treatment options. The region is experiencing a demographic shift with an aging population, which is expected to drive an increase in mitral valve disease cases. Growing awareness about heart health and the availability of advanced treatments is encouraging patients to seek timely medical intervention. Some countries in Asia-Pacific, such as India and Thailand, have become popular destinations for medical tourism, attracting patients from around the world seeking cost-effective yet high-quality healthcare, including mitral valve disease treatment. Governments in several Asian countries are investing in healthcare infrastructure development, research, and training programs to enhance cardiac care capabilities. The region is witnessing the expansion of healthcare facilities, including cardiac centers and specialized hospitals, catering to the growing demand for cardiovascular treatments.

Key Market Players

Corcym UK Limited

Abbott Laboratories Inc

Zydus Lifesciences Limited

Medtronic plc

Edwards Lifesciences Corporation

Affluent Medical SA

ShockWave Medical, Inc.

Valcare Medical

Pfizer Inc

Teva Pharmaceutical Industries Ltd.

Report Scope:

In this report, the Global Mitral Valve Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Mitral Valve Disease Market, By Treatment Type:

  • Repair
  • Replacement
  • Cardiac Resynchronization Therapy
  • Therapeutics

Mitral Valve Disease Market, By Indication:

  • Stenosis
  • Prolapse
  • Regurgitation

Mitral Valve Disease Market, By End-User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Mitral Valve Disease Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Mitral Valve Disease Market.

Available Customizations:

  • Global Mitral Valve Disease market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary End-Users
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Mitral Valve Disease Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Repair, Replacement, Cardiac Resynchronization Therapy, Therapeutics)
    • 5.2.2. By Indication (Stenosis, Prolapse, Regurgitation)
    • 5.2.3. By End-User (Hospitals, Ambulatory Surgical Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Market Map

6. North America Mitral Valve Disease Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Indication
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Mitral Valve Disease Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Mitral Valve Disease Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Mitral Valve Disease Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By End-User

7. Europe Mitral Valve Disease Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Indication
    • 7.2.3. By End-User
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Mitral Valve Disease Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By End-User
    • 7.3.2. United Kingdom Mitral Valve Disease Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By End-User
    • 7.3.3. Italy Mitral Valve Disease Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By End-User
    • 7.3.4. France Mitral Valve Disease Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Mitral Valve Disease Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By End-User

8. Asia-Pacific Mitral Valve Disease Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Indication
    • 8.2.3. By End-User
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Mitral Valve Disease Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Mitral Valve Disease Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan Mitral Valve Disease Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea Mitral Valve Disease Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Mitral Valve Disease Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By End-User

9. South America Mitral Valve Disease Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Indication
    • 9.2.3. By End-User
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Mitral Valve Disease Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By End-User
    • 9.3.2. Argentina Mitral Valve Disease Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By End-User
    • 9.3.3. Colombia Mitral Valve Disease Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By End-User

10. Middle East and Africa Mitral Valve Disease Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Indication
    • 10.2.3. By End-User
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Mitral Valve Disease Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By End-User
    • 10.3.2. Saudi Arabia Mitral Valve Disease Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By End-User
    • 10.3.3. UAE Mitral Valve Disease Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers & Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Mitral Valve Disease Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Corcym UK Limited
  • 14.2. Abbott Laboratories Inc
  • 14.3. Zydus Lifesciences Limited
  • 14.4. Medtronic plc
  • 14.5. Edwards Lifesciences Corporation
  • 14.6. Affluent Medical SA
  • 14.7. ShockWave Medical, Inc.
  • 14.8. Valcare Medical
  • 14.9. Pfizer Inc
  • 14.10. Teva Pharmaceutical Industries Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer